Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Pfizer
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Arcus Biosciences, Inc.
Akeso
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Seagen Inc.
Astellas Pharma Inc
OncoSil Medical Limited
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Duke University
National Cancer Institute (NCI)
Georgetown University
National Health Research Institutes, Taiwan
Memorial Sloan Kettering Cancer Center
Taiho Oncology, Inc.
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
University Health Network, Toronto
National Cancer Institute (NCI)
Enliven Therapeutics
City of Hope Medical Center
Thomas Jefferson University
Astellas Pharma Inc
Akeso
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Grupo Espanol Multidisciplinario del Cancer Digestivo
University of Rochester
ITM Solucin GmbH
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer
Sun Yat-sen University
Toray Industries, Inc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
GERCOR - Multidisciplinary Oncology Cooperative Group
Servicio de Salud Metropolitano Sur Oriente
Gruppo Oncologico del Nord-Ovest
Lisata Therapeutics, Inc.
Seattle Project Corporation